UY35465A - Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) - Google Patents
Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)Info
- Publication number
- UY35465A UY35465A UY0001035465A UY35465A UY35465A UY 35465 A UY35465 A UY 35465A UY 0001035465 A UY0001035465 A UY 0001035465A UY 35465 A UY35465 A UY 35465A UY 35465 A UY35465 A UY 35465A
- Authority
- UY
- Uruguay
- Prior art keywords
- ret
- reorganized
- new compounds
- during transfection
- inhibitors during
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
Esta invención se refiere a nuevos compuestos que son inhibidores de la quinasa Reorganizada Durant e la Transfección (RET), a composiciones farmacéuticas que los contienen, a los procedimientos para su preparación, y a su uso en terapia, solos o c ombinados, para la normalización de la sensibilidad, la motilidad y/o la secreción gastrointestinal y/o trastornos o enfermedades abdominales y/o el tratamiento relacionado con enfermedades relacion adas con la disfunción de RET o en las que la modulación de la actividad de RET puede tener un bene ficio terapéutico que incluye, pero no se limita a, todas las clasificaciones del síndrome del inte stino irritable (SII).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013072683 | 2013-03-15 | ||
| CN2013090059 | 2013-12-20 | ||
| CN2014072449 | 2014-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35465A true UY35465A (es) | 2014-10-31 |
Family
ID=50390154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035465A UY35465A (es) | 2013-03-15 | 2014-03-14 | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US9382238B2 (es) |
| EP (1) | EP2970191B1 (es) |
| JP (1) | JP2016516026A (es) |
| CN (1) | CN105051027A (es) |
| AU (1) | AU2014229233B2 (es) |
| BR (1) | BR112015023618A2 (es) |
| CA (1) | CA2905627A1 (es) |
| CL (1) | CL2015002514A1 (es) |
| CR (1) | CR20150490A (es) |
| CY (1) | CY1118730T1 (es) |
| DK (1) | DK2970191T3 (es) |
| DO (1) | DOP2015000244A (es) |
| EA (1) | EA029296B1 (es) |
| ES (1) | ES2616655T3 (es) |
| HR (1) | HRP20170363T1 (es) |
| HU (1) | HUE033423T2 (es) |
| IL (1) | IL241161A0 (es) |
| LT (1) | LT2970191T (es) |
| ME (1) | ME02664B (es) |
| MX (1) | MX2015012286A (es) |
| NZ (1) | NZ628388A (es) |
| PE (1) | PE20151538A1 (es) |
| PH (1) | PH12015502044A1 (es) |
| PL (1) | PL2970191T3 (es) |
| PT (1) | PT2970191T (es) |
| RS (1) | RS55710B1 (es) |
| SG (1) | SG11201506695UA (es) |
| SI (1) | SI2970191T1 (es) |
| TW (1) | TW201524958A (es) |
| UA (1) | UA115264C2 (es) |
| UY (1) | UY35465A (es) |
| WO (1) | WO2014141187A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3205654T3 (pl) | 2010-05-20 | 2019-08-30 | Array Biopharma, Inc. | Związki makrocykliczne jako inhibitory kinazy TRK |
| AU2015313894A1 (en) * | 2014-09-08 | 2017-03-23 | Glaxosmithkline Intellectual Property Development Limited | Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide |
| US9918974B2 (en) | 2014-09-10 | 2018-03-20 | Glaxosmithkline Intellectual Property Development Limited | Pyridone derivatives as rearranged during transfection (RET) kinase inhibitors |
| DK3191449T3 (da) * | 2014-09-10 | 2020-08-03 | Glaxosmithkline Ip Dev Ltd | Forbindelser som ret- (rearranged during transfection) hæmmere |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP4292594A3 (en) * | 2015-11-02 | 2024-03-27 | Blueprint Medicines Corporation | Inhibitors of ret |
| WO2017145050A1 (en) | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer |
| AU2017232610B2 (en) * | 2016-03-16 | 2021-07-22 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| AU2017263174A1 (en) | 2016-05-13 | 2018-12-13 | Instituto de Medicina Molecular João Lobo Antunes | Methods of treating diseases associated with ILC3 cells |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018213329A1 (en) | 2017-05-15 | 2018-11-22 | Blueprint Medicines Corporation | Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity |
| US10093648B1 (en) * | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
| TW202410896A (zh) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| RS65127B1 (sr) | 2018-04-03 | 2024-02-29 | Blueprint Medicines Corp | Ret inhibitor za primenu u lečenju kancera koji ima ret alteraciju |
| CN109096264B (zh) * | 2018-08-28 | 2019-08-23 | 山东理工职业学院 | Ret抑制剂及其制备方法、组合物和用途 |
| WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| AU2020257301A1 (en) | 2019-04-18 | 2021-11-11 | The Johns Hopkins University | Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof |
| WO2021164742A1 (zh) * | 2020-02-20 | 2021-08-26 | 广州白云山医药集团股份有限公司白云山制药总厂 | 喹啉类化合物 |
| AR121914A1 (es) * | 2020-04-27 | 2022-07-20 | Lilly Co Eli | Compuestos útiles para inhibir la quinasa ret |
| TWI786742B (zh) * | 2020-07-23 | 2022-12-11 | 大陸商深圳晶泰科技有限公司 | 吡啶酮類化合物及其製備方法和應用 |
| AU2021376367B2 (en) | 2020-11-06 | 2024-08-01 | Eli Lilly And Company | Pyrazole derivatives asr et kinase inhibitors |
| US20240270855A1 (en) | 2021-06-03 | 2024-08-15 | Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud | Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit |
| CN115626880B (zh) * | 2022-11-15 | 2023-11-14 | 常州大学 | 3-硝基-5-氰基三氟甲苯的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020060160A (ko) | 1999-08-12 | 2002-07-16 | 파마시아 이탈리아 에스.피.에이. | 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도 |
| CA2430151A1 (en) * | 2000-11-27 | 2002-06-20 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| DE10201764A1 (de) | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| US7977338B2 (en) * | 2006-10-16 | 2011-07-12 | Novartis Ag | Phenylacetamides being FLT3 inhibitors |
| EP2099774A4 (en) | 2006-11-15 | 2010-11-24 | Ym Biosciences Australia Pty L | INHIBITORS OF KINASEACTIVITY |
| US20130035326A1 (en) | 2009-08-19 | 2013-02-07 | Ambit Biosciences Corporation | Biaryl compounds and methods of use thereof |
| WO2012082817A1 (en) | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| US8937071B2 (en) | 2013-03-15 | 2015-01-20 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
-
2014
- 2014-03-14 EP EP14713598.2A patent/EP2970191B1/en active Active
- 2014-03-14 PL PL14713598T patent/PL2970191T3/pl unknown
- 2014-03-14 UA UAA201510041A patent/UA115264C2/uk unknown
- 2014-03-14 SI SI201430170A patent/SI2970191T1/sl unknown
- 2014-03-14 US US14/775,772 patent/US9382238B2/en not_active Expired - Fee Related
- 2014-03-14 CA CA2905627A patent/CA2905627A1/en not_active Abandoned
- 2014-03-14 TW TW103109315A patent/TW201524958A/zh unknown
- 2014-03-14 CN CN201480015907.3A patent/CN105051027A/zh active Pending
- 2014-03-14 NZ NZ628388A patent/NZ628388A/en not_active IP Right Cessation
- 2014-03-14 SG SG11201506695UA patent/SG11201506695UA/en unknown
- 2014-03-14 AU AU2014229233A patent/AU2014229233B2/en not_active Ceased
- 2014-03-14 JP JP2015562529A patent/JP2016516026A/ja active Pending
- 2014-03-14 PT PT147135982T patent/PT2970191T/pt unknown
- 2014-03-14 DK DK14713598.2T patent/DK2970191T3/en active
- 2014-03-14 WO PCT/IB2014/059817 patent/WO2014141187A1/en active Application Filing
- 2014-03-14 MX MX2015012286A patent/MX2015012286A/es unknown
- 2014-03-14 BR BR112015023618A patent/BR112015023618A2/pt not_active IP Right Cessation
- 2014-03-14 ME MEP-2017-60A patent/ME02664B/me unknown
- 2014-03-14 HU HUE14713598A patent/HUE033423T2/en unknown
- 2014-03-14 EA EA201591738A patent/EA029296B1/ru not_active IP Right Cessation
- 2014-03-14 RS RS20170177A patent/RS55710B1/sr unknown
- 2014-03-14 PE PE2015001878A patent/PE20151538A1/es not_active Application Discontinuation
- 2014-03-14 ES ES14713598.2T patent/ES2616655T3/es active Active
- 2014-03-14 LT LTEP14713598.2T patent/LT2970191T/lt unknown
- 2014-03-14 UY UY0001035465A patent/UY35465A/es unknown
-
2015
- 2015-09-03 IL IL241161A patent/IL241161A0/en unknown
- 2015-09-08 CL CL2015002514A patent/CL2015002514A1/es unknown
- 2015-09-10 PH PH12015502044A patent/PH12015502044A1/en unknown
- 2015-09-14 CR CR20150490A patent/CR20150490A/es unknown
- 2015-09-15 DO DO2015000244A patent/DOP2015000244A/es unknown
-
2016
- 2016-06-02 US US15/171,229 patent/US9789100B2/en not_active Expired - Fee Related
-
2017
- 2017-03-06 HR HRP20170363TT patent/HRP20170363T1/hr unknown
- 2017-03-14 CY CY20171100319T patent/CY1118730T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35465A (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) | |
| CR20170093A (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfección) | |
| DOP2016000295A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| CY1123388T1 (el) | Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| CY1120866T1 (el) | Παρεμποδιστες dna-pk | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| EA201991484A1 (ru) | Лекарственные формы энзалутамида | |
| DOP2017000035A (es) | Inhibidores de la proteina quinasa c y metodos de su uso | |
| EA201892740A2 (ru) | Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk) | |
| CR20140512A (es) | Dispositivos y metodos para la fabricación de aditivos de componentes de implante | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| GT201200147A (es) | Antagonistas de espiro-oxindol de mdm2 | |
| CO2017002268A2 (es) | Inhibidores espirocíclicos de catepsina c | |
| ECSP14024526A (es) | Derivados bicíclicos de pirazinona | |
| ECSP14017586A (es) | Derivados de tetrahidro-quinazolinona | |
| GT201600027A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| CY1122763T1 (el) | Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων | |
| CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| CO2020005485A2 (es) | Administración oral de análogos del péptido glp-1 | |
| EA201692278A1 (ru) | Комбинации формотерола и будесонида для лечения хобл | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. |